BioSyent (CVE:RX) Sets New 52-Week High – Still a Buy?

BioSyent Inc. (CVE:RX) hit a new 52-week high during trading on Friday . The company traded as high as C$11.98 and last traded at C$11.95, with a volume of 1111 shares. The stock had previously closed at C$11.61.

BioSyent Price Performance

The company has a quick ratio of 6.91, a current ratio of 6.13 and a debt-to-equity ratio of 3.19. The stock has a market capitalization of C$138.85 million, a PE ratio of 19.97 and a beta of 0.93. The stock’s 50-day moving average is C$11.21 and its 200 day moving average is C$10.54.

Insider Buying and Selling

In related news, Senior Officer Robert Joseph March sold 4,775 shares of the stock in a transaction on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Also, insider FAX Capital Corp. sold 230,800 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of C$11.12, for a total transaction of C$2,566,496.00. In the last three months, insiders sold 239,132 shares of company stock valued at $2,661,482. Company insiders own 33.65% of the company’s stock.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.